Novo Nordisk | NVO - Cash And Equivalent


Novo Nordisk reported DKK38.94B in Cash and Equivalent for its fiscal quarter ending in March of 2025.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
Bausch Health Companies USD 1.31B 419M Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Phibro Animal Health USD 55.49M 17.28M Dec/2025
Prestige Brands USD 62.37M 56.73M Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Zoetis USD 2.08B 649M Sep/2025